A rapid, high-throughput viability assay for Blastocystis spp. reveals metronidazole resistance and extensive subtype-dependent variations in drug susceptibilities

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 2, 2011, Pages 637-648

  Mirza, Haris ^a   Teo, Joshua D W ^a   Upcroft, Jacqui ^b   Tan, Kevin S W ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; CHLOROQUINE; COTRIMOXAZOLE; DOXYCYCLINE; EMETINE; FURAZOLIDONE; IODOACETAMIDE; MEFLOQUINE; METRONIDAZOLE; NITAZOXANIDE; ORNIDAZOLE; PAROMOMYCIN; PYRIMETHAMINE; QUINICRINE; QUININE; RESAZURIN; TINIDAZOLE; UNCLASSIFIED DRUG;

ARTICLE; BLASTOCYSTIS; BLASTOCYSTOSIS; DRUG SCREENING; DRUG SENSITIVITY; HIGH THROUGHPUT SCREENING; MICROANALYSIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIPROTOZOAL AGENTS; BLASTOCYSTIS; BLASTOCYSTIS INFECTIONS; DRUG RESISTANCE; EMETINE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; METRONIDAZOLE; OXAZINES; OXIDATION-REDUCTION; PARASITIC SENSITIVITY TESTS; REPRODUCIBILITY OF RESULTS; SPECIES SPECIFICITY; TETRAZOLIUM SALTS; TIME FACTORS; XANTHENES;

EID: 78751690774     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00900-10     Document Type: Article

References (75)

1. Abdulla, M. H., K. C. Lim, M. Sajid, J. H. McKerrow, and C. R. Caffrey. 2007. Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Med. 4:e14.
2. Adagu, I. S., D. Nolder, D. C. Warhurst, and J. F. Rossignol. 2002. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J. Antimicrob. Chemother. 49:103-111.
3. Armentia, A., et al. 1993. Urticaria by Blastocystis hominis. Successful treatment with paromomycin. Allergol. Immunopathol. 21:149-151.
4. Bassily, S., Z. Farid, N. A. el-Masry, and E. M. Mikhail. 1987. Treatment of intestinal E. histolytica and G. lamblia with metronidazole, tinidazole and ornidazole: a comparative study. J. Trop. Med. Hyg. 90:9-12.
5. Bénéré, E., R. A. da Luz, M. Vermeersch, P. Cos, and L. Maes. 2007. A new quantitative in vitro microculture method for Giardia duodenalis trophozoites. J. Microbiol. Methods 71:101-106.
6. Boorom, K. F., et al. 2008. Oh my aching gut: irritable bowel syndrome, Blastocystis, and asymptomatic infection. Parasit. Vectors 1:40.
7. Boreham, P. F. L., N. C. Smith, and R. W. Shepherd. 1988. Drug resistance and treatment of giardiasis, p. 3-7. In P. M. Wallis and B. R. Hammond (ed.), Advances in Giardia research. University of Calgary Press, Calgary, Alberta, Canada.
8. Brasseur, P., and L. Favennec. 1995. Two cases of giardiasis unsuccessfully treated by albendazole. Parasite 2:422.
9. 2O-producing NADH oxidase from the protozoan parasite Giardia duodenalis. Eur. J. Biochem. 241:155-161.
10. Chintana, T., P. Sucharit, V. Mahakittikun, C. Siripanth, and W. Suphadtanaphongs. 1986. In vitro studies on the sensitivity of local Entamoeba histolytica to anti-amoebic drugs. Southeast Asian J. Trop. Med. Public Health 17:591-594.
11. Chen, X. Q., et al. 1997. A survey of Blastocystis sp. in rodents. Lab. Anim. Sci. 47:91-94.
12. Crowell, A. L., K. A. Sanders-Lewis, and W. E. Secor. 2003. In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis. Antimicrob. Agents Chemother. 47:1407-1409.
13. Davidson, R. N., M. den Boer, and K. Ritmeijer. 2009. Paromomycin. Trans. R. Soc. Trop. Med. Hyg. 103:653-660.
14. De Logu, A., et al. 2003. Comparison of the susceptibility testing of clinical isolates of Mycobacterium tuberculosis by the XTT colorimetric method and the NCCLS standards method. Int. J. Antimicrob. Agents 21:244-250.
15. Donald, P. R., et al. 2000. Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis. Antimicrob. Agents Chemother. 44:3285-3287.
16. Dunn, L. A., and P. F. Boreham. 1991. The in-vitro activity of drugs against Blastocystis hominis. J. Antimicrob. Chemother. 27:507-516.
17. Dunn, L. A., et al. 2010. A new-generation 5-nitroimidazole can induce highly metronidazole-resistant Giardia lamblia in vitro. Int. J. Antimicrob. Agents 36:37-42.
18. Engel, J. C., P. S. Doyle, and J. H. McKerrow. 1999. Trypanocidal effect of cysteine protease inhibitors in vitro and in vivo in experimental Chagas disease. Medicina (Buenos Aires) 59:171-175.
19. Gargala, G. 2008. Drug treatment and novel drug target against Cryptosporidium. Parasite 15:275-281.
20. Glass, R. H., et al. 1991. The resazurin reduction test provides an assessment of sperm activity. Fertil. Steril. 56:743-746.
21. Güven, A. 2003. Amebiasis in the newborn. Indian J. Pediatr. 70:437-438.
22. Harder, A., G. Greif, and A. Haberkorn. 2001. Chemotherapeutic approaches to protozoa: Giardia, Trichomonas and Entamoeba - current level of knowledge and outlook. Parasitol. Res. 87:785-786.
23. Haresh, K., K. Suresh, A. Khairul Anus, and S. Saminathan. 1999. Isolate resistance of Blastocystis hominis to metronidazole. Trop. Med. Int. Health 4:274-277.
24. Hussein, E. M., A. M. Hussein, M. M. Eida, and M. M. Atwa. 2008. Pathophysiological variability of different genotypes of human Blastocystis hominis Egyptian isolates in experimentally infected rats. Parasitol. Res. 102:853-860.
25. Katsarou-Katsari, A., et al. 2008. Acute urticaria associated with amoeboid forms of Blastocystis sp. subtype 3. Acta Derm. Venereol. 88:80-81.
26. Krook, A., B. Lindström, J. Kjellander, G. Järnerot, and L. Bodin. 1981. Relation between concentrations of metronidazole and Bacteroides spp in faeces of patients with Crohn's disease and healthy individuals. J. Clin. Pathol. 34:645-650.
27. Kurniawan, A., et al. 2009. Intestinal parasitic infections in HIV/AIDS patients presenting with diarrhoea in Jakarta, Indonesia. Trans. R. Soc. Trop. Med. Hyg. 103:892-898.
28. Leitsch, D., D. Kolarich, and M. Duchêne. 2010. The flavin inhibitor diphenyleneiodonium renders Trichomonas vaginalis resistant to metronidazole, inhibits thioredoxin reductase and flavin reductase, and shuts off hydrogenosomal enzymatic pathways. Mol. Biochem. Parasitol. 171: 17-24.
29. Leonard, B., et al. 2008. Inter- and intra-assay reproducibility of microplate Alamar Blue assay results for isoniazid, rifampicin, ethambutol, streptomycin, ciprofloxacin, and capreomycin drug susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 46:3526-3529.
30. Li, Q., C. Maddox, L. Rasmussen, J. V. Hobarth, and L. E. White. 2009. Assay development and high-throughput antiviral drug screening against Bluetongue virus. Antiviral Res. 83:267-273.
31. Löfmark, S., C. Edlund, and C. E. Nord. 2010. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin. Infect. Dis. 50(Suppl. 1):S16-S23.
32. Marino, A., R. Costa, and G. De Natale. 1990. Cardiotoxicity of emetine. Clin. Ter. 133:131-143.
33. Markell, E. K. 1995. Is there any reason to continue treating Blastocystis infections? Clin. Infect. Dis. 21:104-105.
34. McBride, J., P. R. Ingram, F. L. Henriquez, and C. W. Roberts. 2005. Development of colorimetric microtiter plate assay for assessment of antimicrobials against Acanthamoeba. J. Clin. Microbiol. 43:629-634.
35. Mehraj, V., J. Hatcher, S. Akhtar, G. Rafique, and M. A. Beg. 2008. Prevalence and factors associated with intestinal parasitic infection among children in an urban slum of Karachi. PLoS One 3:e3680.
36. Mirza, H., and K. S. Tan. 2009. Blastocystis exhibits inter- and intra-subtype variation in cysteine protease activity. Parasitol. Res. 104:355-361.
37. Moghaddam, D. D., E. Ghadirian, and M. Azmi. 2005. Blastocystis hominis and the evaluation of efficacy of metronidazole and trimethoprim/ sulfamethoxazole. Parasitol. Res. 96:273-275.
38. Muzaffar, J., K. Madan, M. P. Sharma, and P. Kar. 2006. Randomized, single-blind, placebo-controlled multicenter trial to compare the efficacy and safety of metronidazole and satranidazole in patients with amebic liver abscess. Dig. Dis. Sci. 51:2270-2273.
39. Noël, C., et al. 2005. Molecular phylogenies of Blastocystis isolates from different hosts: implications for genetic diversity, identification of species, and zoonosis. J. Clin. Microbiol. 43:348-355.
40. Noureldin M. S., A. A. Shaltout, E. M. El Hamshary, and M. E. Ali. 1999. Opportunistic intestinal protozoal infections in immunocompromised children. J. Egypt. Soc. Parasitol. 29:951-961.
41. O'Brien, J., I. Wilson, T. Orton, and F. Pognan. 2000. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem. 267:5421-5426.
42. Olson, J. E., G. K. Lee, A. Semenov, and P. J. Rosenthal. 1999. Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors. Bioorg. Med. Chem. 7:633-668.
43. Orozco, E., L. A. Marchat, C. Gómez, C. López-Camarillo, and D. G. Pérez. 2009. Drug resistance mechanisms in Entamoeba histolytica, Giardia lamblia, Trichomonas vaginalis, and opportunistic anaerobic protozoa, p. 549-559. In G. A. Jacoby, R. Elston, P. R. Bonneau, and I. M. Douglas (ed.), Antimicrobial drug resistance; mechanisms of drug resistance, vol. 1. Humana Press, Totowa, NJ.
44. Parikh, S., et al. 2005. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 49:2983-2985.
45. Pasqui, A. L., et al. 2004. Chronic urticaria and Blastocystis hominis infection: a case report. Eur. Rev. Med. Pharmacol. Sci. 8:117-120.
46. Perrot, S., H. Dutertre-Catella, C. Martin, J. M. Warnet, and P. Rat. 2003. A new nondestructive cytometric assay based on resazurin metabolism and an organ culture model for the assessment of corneal viability. Cytometry A 55:7-14. (Pubitemid 37522516)
47. Petrenko, Y. A., N. A. Gorokhova, E. N. Tkachova, and A. Y. Petrenko. 2005. The reduction of Alamar Blue by peripheral blood lymphocytes and isolated mitochondria. Ukr. Biokhim. Zh. 77:100-105.
48. Puthia, M. K., J. Lu, and K. S. Tan. 2008. Blastocystis ratti contains cysteine proteases that mediate interleukin-8 response from human epithelial cells in an NF-kappaB-dependent manner. Eukaryot. Cell 7:435-443.
49. Quiros-Buelna, E. 1989. Furazolidone and metronidazole for treatment of giardiasis in children. Scand. J. Gastroenterol. Suppl. 169:65-69.
50. Rosenthal, P. J., G. K. Lee, and R. E. Smith. 1993. Inhibition of a Plasmodium vinckei cysteine proteinase cures murine malaria. J. Clin. Invest. 91: 1052-1056.
51. Rossignol, J. F., S. M. Kabil, M. Said, H. Samir, and A. M. Younis. 2005. Effects of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis hominis. Clin. Gastroenterol. Hepatol. 3:987-991.
52. Stensvold, C. R., et al. 2007. Terminology for Blastocystis subtypes - a consensus. Trends Parasitol. 23:93-96.
53. Stensvold, C. R., M. C. Arendrup, H. V. Nielsen, A. Bada, and S. Thorsen. 2008. Symptomatic infection with Blastocystis sp. subtype 8 successfully treated with trimethoprim-sulfamethoxazole. Ann. Trop. Med. Parasitol. 102:271-274.
54. Stensvold, C. R., et al. 2009. Blastocystis: unravelling potential risk factors and clinical significance of a common but neglected parasite. Epidemiol. Infect. 137:1655-1663.
55. Stensvold, C. R., H. V. Smith, R. Nagel, K. E. Olsen, and R. J. Traub. 2010. Eradication of Blastocystis carriage with antimicrobials: reality or delusion? J. Clin. Gastroenterol. 44:85-90.
56. Sugie, H., R. Russin, and M. A. Verity. 1984. Emetine myopathy: two case reports with pathobiochemical analysis. 7:54-59.
57. Tan, K. S. 2008. New insights on classification, identification, and clinical relevance of Blastocystis spp. Clin. Microbiol. Rev. 21:639-665.
58. Tan, K. S., H. Mirza, D. W. T. Joshua, B. Wu, and P. A. MacAry. 2010. Current views on the clinical relevance of Blastocystis spp. Curr. Infect. Dis. Rep. 12:28-35.
59. Taçsova, Y., B. Sahin, S. Koltaçs, and S. Paydaçs. 2000. Clinical significance and frequency of Blastocystis hominis in Turkish patients with hematological malignancy. Acta Med. Okayama 54:133-136.
60. Theodos, C. M., J. K. Griffiths, J. D'Onfro, A. Fairfield, and S. Tzipori. 1998. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob. Agents Chemother. 42:1959-1965.
61. Upcroft, J. A., and P. Upcroft. 1993. Drug resistance and Giardia. Parasitol. Today 9:187-190.
62. Upcroft, J. A., R. Mitchell, N. Chen, and P. Upcroft. 1996. Albendazole resistance in Giardia is correlated with cytoskeletal changes but not with a mutation at amino acid 200 in beta-tubulin. Microb. Drug Resist. 2:303-308.
63. Upcroft, J. A., R. W. Campbell, and P. Upcroft. 1996. Quinacrine resistant Giardia duodenalis. Parasitology 112:309-313.
64. Upcroft, J. A., R. W. Campbell, K. Benakli, P. Upcroft, and P. Vanelle. 1999. Efficacy of 5-nitroimidazoles against metronidazole-susceptible and resistant Giardia, Trichomonas and Entamoeba spp. Antimicrob. Agents Chemother. 43:73-76.
65. Upcroft, P., and J. A. Upcroft. 2001. Drug targets and mechanisms of resistance in anaerobic protozoa. Clin. Microbiol. Rev. 14:150-164.
66. Upcroft, J. A., et al. 2006. 5-Nitroimidazole drugs effective against metronidazole-resistant Trichomonas vaginalis and Giardia duodenalis. Antimicrob. Agents Chemother. 50:344-347.
67. Valsecchi, R., P. Leghissa, and V. Greco. 2004. Cutaneous lesions in Blastocystis hominis infection. Acta Derm. Venereol. 84:322-323.
68. Vdovenko, A. A., and J. E. Williams. 2000. Blastocystis hominis: neutral red supravital staining and its application to in vitro drug sensitivity testing. Parasitol. Res. 86:573-581.
69. Wasilewski, M. M., K. C. Lim, J. Phillips, and J. H. McKerrow. 1996. Cysteine protease inhibitors block schistosome hemoglobin degradation in vitro and decrease worm burden and egg production in vivo. Mol. Biochem. Parasitol. 81:179-189.
70. Wawrzyniak, I., et al. 2008. Complete circular DNA in the mitochondria-like organelles of Blastocystis hominis. Int. J. Parasitol. 38:1377-1382.
71. Wu, B., J. Yin, C. Texier, M. Roussel, and K. S. Tan. 2010. Blastocystis legumain is localized on the cell surface, and specific inhibition of its activity implicates a pro-survival role for the enzyme. J. Biol. Chem. 285:1790-1798.
72. Yakoob, J., W. Jafri, N. Jafri, M. Islam, and M. A. Beg. 2004. In vitro susceptibility of Blastocystis hominis isolated from patients with irritable bowel syndrome. Br. J. Biomed. Sci. 61:75-77.
73. Zaman, V., and M. Zaki. 1996. Resistance of Blastocystis hominis cysts to metronidazole. Trop. Med. Int. Health 1:677-678.
74. Zhang, J. H., T. D. Chung, and K. R. Oldenburg. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:67-73.
75. Zierdt, C. H., J. C. Swan, and J. Hosseini. 1983. In vitro response of Blastocystis hominis to antiprotozoal drugs. J. Protozool. 30:332-334.